Horizon has developed a set of precisely defined cell line-derived reference standards to support Biocartis' recently launched Idylla™ microsatellite instability (MSI) Assay.
Erwin Sablon, VP Alliance Management & Partnerships of Biocartis: "The collaboration between Biocartis and Horizon has contributed greatly to the successful market launch of the Idylla™ MSI Assay in July 2018. We continue to be impressed with the quality of Horizon's reference standards."
Incorporation of Horizon's Reference Standards has enabled CareDx to progress through regulatory hurdles. CareDx's cfDNA test is designed to monitor injury to transplanted organs, in particular heart and kidney, in transplant recipients. This allows clinicians to better manage patient health outcomes
Dr. John J. Sninsky, CSO of CareDx: "I have been working with Horizon's scientists for more than five years, and am continually impressed by their understanding of diagnostic requirements. At CareDx, it is our goal to accelerate patient access to clinical data using next generation sequencing technology. This collaboration with Horizon has the potential to advance us to this goal, and demonstrates CareDx's continued quality and regulatory leadership."